close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Pharmaceutical Whistleblowers Tell Their Tales Through Blogs, Congress Responds

NEWTOWN, PA, May 4, 2007 – This week’s edition of the PharmaBlogs: Week in Review e-newsletter addresses the continuing aftershocks of the “Zubillaga saga”, Congress’ attention to recent whistleblowers, and potentially tacky marketing ploys. Christiane Truelove, editor of Med Ad News and R&D Directions, summarizes the thoughts of popular industry bloggers on these topics.

Two recent Big Pharma whistleblowing incidents have unfolded almost entirely through blogs, namely the blog of Dr. Peter Rost. This caught the attention of California Democrat Rep. Peter Stark, who requested that the Office of the Inspector General (OIG) conduct an investigation of FDA's oversight of pharmaceutical marketing to physicians. BrandweekRx claims that these events mark a turning point in the industry’s relationship with the media, stating “How many other Congressional inquiry demands have been based on blog coverage?” 

About going to Dr. Rost to spread the news about her complaint, this week’s Pfizer whistleblower says “I tried going to Pfizer, hired a lawyer, and called the OIG. He [Dr. Rost] was willing to do what everyone else was not.” According to BrandWeekRx, both whistleblowers claimed to go to the Office of Inspector General first and got no response, so they went to Dr. Rost.

On the lighter side of this week’s blogs, it is noted that AstraZeneca sales reps plan to set up tables in doctor’s offices and distribute pink flowers and pink cupcakes along with breast cancer drug information to patients. Christiane notes “The bloggers writing about this gave the impression that they think this initiative is tacky. They’re also all men”. She then describes a truly tacky sunbathing sales rep tale she heard in the 90s and hopes tacky marketing tactics like these don’t make a comeback.

About PharmaBlogs: Week in Review
Designed as a time-effective approach to keeping current on the industry’s blog discussions, PharmaBlogs: Week in Review is the first online newsletter focused on recapping pharmaceutical blogs. The e-newsletter is published by industry information provider Engel Publishing Partners and sent to your e-mail inbox each Friday.

Pharma professionals who wish to subscribe to PharmaBlogs: Week in Review may visit www.pharmalive.com/enewsletters.

About Engel Publishing Partners
For 25 years, Engel Publishing Partners has been the source that pharmaceutical executives turn to for the information they need to create competitive business strategies. Engel Publishing Partners carries a full product line offering industry-leading publications, informative newsletters, and data-rich interactive products. Through these channels, Engel disseminates original and un-biased content that provides insight into industry trends and events, as well as extensive analysis of companies, products, and pipelines.

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...